European Equity pre-Market Summary - 11th August 2026: Futures flat, M&A and earnings dominate equity newsflow

Pre-market summaries of this kind are a roundup rather than a single catalyst; the dominant item is the reported AstraZeneca approach for Bristol Myers Squibb, and the pattern with reported cross-border pharma megadeals of this shape is that the target trades toward the reported terms while the acquirer gives back ground, with the spread between the two becoming a live read on completion risk. A mostly share-based structure matters here: it caps the cash financing question but ties the target's implied value to the acquirer's own share price, so the exchange ratio and any collar become the detail that determines where the pair trades. Reported deals sourced to a single outlet ahead of a formal announcement have historically either been confirmed quickly or denied, and the tell is whether the companies issue a statement under takeover panel rules, which in the UK forces a put-up-or-shut-up clock. The Glencore consortium move on Sherritt fits the established pattern of traders securing refining and processing capacity rather than mine supply, and cobalt exposure of this kind tends to trade on strategic control rather than near-term earnings. Elsewhere the tape is mixed: steel and mining upgrades against a life insurer downgrade, and flat index futures suggest the M&A idiosyncrasics, not the macro, set the opening tone. The follow-ons are any company statements, panel deadlines, and whether the reported mid-August timeline firms up.